Top Latest High-Quality Research on Trastuzumab (2023–2026)

Compiled as of April 28, 2026 | Sources: PubMed | Filtered for Phase III RCTs, Systematic Reviews, Meta-Analyses, and landmark Clinical Guidelines

🔬 CATEGORY 1 — Landmark Phase III RCTs

1. DESTINY-Breast09: T-DXd + Pertuzumab vs. Standard First-Line Therapy

Tolaney SM et al. Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2026. PMID: 41160818

• Phase III trial (n=770 patients, 1:1:1 randomization) comparing T-DXd + pertuzumab vs. T-DXd alone vs. taxane + trastuzumab + pertuzumab (THP) as first-line therapy in HER2+ metastatic breast cancer.
• T-DXd + pertuzumab achieved a median PFS of 40.7 months vs. 26.9 months with THP (HR 0.56; 95% CI 0.44–0.71; P<0.00001).
• Objective response rate: 85.1% vs. 78.6%; complete responses: 15.1% vs. 8.5%.
• ILD/pneumonitis occurred in 12.1% of patients on T-DXd + pertuzumab (2 fatal events).
• Clinical Significance: This is the first Phase III trial to demonstrate superiority of a T-DXd-based regimen over the previous standard-of-care THP in the first-line setting — a practice-changing result.

2. KATHERINE Final Analysis: T-DM1 Survival Benefit in Residual HER2+ Early Breast Cancer

Geyer CE et al. Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer. N Engl J Med. 2025. PMID: 39813643

• Final analysis of the landmark KATHERINE trial (median follow-up 8.4 years), comparing adjuvant T-DM1 vs. trastuzumab in HER2+ early breast cancer with residual disease after neoadjuvant therapy.
• 7-year invasive disease-free survival: 80.8% (T-DM1) vs. 67.1% (trastuzumab) — a 13.7 percentage point difference.
• Overall survival benefit confirmed: HR 0.66 (95% CI 0.51–0.87; P=0.003). 7-year OS: 89.1% vs. 84.4%.
• Grade ≥3 adverse events: 26.1% (T-DM1) vs. 15.7% (trastuzumab).
• Clinical Significance: Provides the first definitive OS benefit for T-DM1 in the adjuvant setting after neoadjuvant failure — cementing its role as standard of care.

3. DESTINY-Breast06: T-DXd Extends into HER2-Low and HER2-Ultralow Disease

Bardia A et al. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. N Engl J Med. 2024. PMID: 39282896

• Phase III trial (n=866) in HR+, HER2-low (IHC 1+ or 2+/ISH−) and HER2-ultralow (IHC 0 with membrane staining) metastatic breast cancer after ≥1 line of endocrine-based therapy.
• Median PFS: 13.2 months (T-DXd) vs. 8.1 months (chemotherapy) in HER2-low patients (HR 0.62; 95% CI 0.52–0.75; P<0.001).
• Benefit also observed in HER2-ultralow exploratory population.
• ILD/pneumonitis: 11.3% with T-DXd (3 grade-5 events).
• Clinical Significance: Expands the therapeutic actionability of T-DXd to patients who were previously considered HER2-negative, fundamentally broadening who can benefit from HER2-directed therapy.

4. DESTINY-Gastric04: T-DXd vs. Ramucirumab + Paclitaxel in Gastric Cancer

Shitara K et al. Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. N Engl J Med. 2025. PMID: 40454632

• Phase III trial (n=494) in HER2+ metastatic gastric/GEJ adenocarcinoma, second-line after trastuzumab-based therapy.
• Median OS: 14.7 months (T-DXd) vs. 11.4 months (ramucirumab + paclitaxel) (HR 0.70; 95% CI 0.55–0.90; P=0.004).
• Confirmed objective response rate: 44.3% vs. 29.1%.
• ILD/pneumonitis: 13.9% with T-DXd (mainly grades 1–2).
• Clinical Significance: Establishes T-DXd as the preferred second-line standard of care in HER2+ gastric cancer, replacing the previous ramucirumab + paclitaxel standard.

5. KEYNOTE-811: Pembrolizumab + Trastuzumab + Chemotherapy in HER2+ Gastric Cancer

Janjigian YY et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma. Lancet. 2023 Dec 9. PMID: 37871604

• Phase III (n=698), randomized trial in first-line HER2+ gastric/GEJ adenocarcinoma.
• Median PFS: 10.0 months (pembrolizumab) vs. 8.1 months (placebo) (HR 0.73; P=0.0002).
• Overall survival: 20.0 vs. 16.9 months (HR 0.87; P=0.084 — did not reach statistical significance).
• PD-L1 CPS ≥1 subgroup showed a stronger OS benefit.
• Clinical Significance: Pembrolizumab + trastuzumab + chemotherapy is an FDA-approved first-line regimen in HER2+/PD-L1+ gastric cancer; this analysis provides the long-term efficacy and survival data.

6. DESTINY-Breast02: T-DXd vs. Physician's Choice in T-DM1-Pretreated HER2+ MBC

André F et al. Trastuzumab deruxtecan versus treatment of physician's choice in HER2-positive metastatic breast cancer (DESTINY-Breast02). Lancet. 2023. PMID: 37086745

• Phase III (n=608), randomized, open-label, multicentre trial in T-DM1-refractory HER2+ metastatic breast cancer.
• Median PFS: 17.8 months (T-DXd) vs. 6.9 months (physician's choice) (HR 0.36; P<0.0001).
• Clinical Significance: Confirmed T-DXd as the standard of care after T-DM1 failure, leading to regulatory approvals globally.

📊 CATEGORY 2 — Systematic Reviews & Meta-Analyses

7. Efficacy and Safety of T-DXd in Breast Cancer: Systematic Review & Meta-Analysis

Dowling GP et al. Efficacy and Safety of Trastuzumab Deruxtecan in Breast Cancer. Clin Breast Cancer. 2023 Dec. PMID: 37775347

• Pooled analysis of 6 clinical trials (n=1,593 patients).
• Median PFS across trials: 11.1–22.1 months.
• T-DXd vs. control: PFS benefit (OR 0.38; 95% CI 0.32–0.45); OS benefit (OR 0.61; 95% CI 0.48–0.78).
• Objective response rates: 37–79.9%.
• Most common high-grade AEs: anemia and neutropenia; ILD is the most serious class-specific AE.

8. ADCs in HER2-Low Metastatic Breast Cancer: Network Meta-Analysis

Schettini F et al. Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer. Cancer Treat Rev. 2025. PMID: 39709655

• Network meta-analysis of 3 RCTs (n=956) comparing T-DXd, sacituzumab govitecan (SG), and datopotamab deruxtecan (Dato-DXd) in HER2-low MBC.
• T-DXd and SG had similar PFS and OS in HR+/HER2-low MBC; P-score slightly favored T-DXd overall.
• T-DXd was the only ADC with significant OS benefit over chemotherapy in HR+/HER2-low.
• Safety: T-DXd associated with more ILD, thrombocytopenia, and fatigue; SG with more neutropenia, alopecia, diarrhea.

📋 CATEGORY 3 — Clinical Practice Guidelines

9. ASCO-CAP HER2 Testing in Breast Cancer: 2023 Guideline Update

Wolff AC et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-CAP Guideline Update. J Clin Oncol. 2023 Aug 1. PMID: 37284804

• Affirms 2018 ASCO-CAP HER2 testing recommendations.
• Acknowledges the new clinical relevance of distinguishing IHC 0 from IHC 1+ due to T-DXd's activity in HER2-low cancers (DESTINY-Breast04 data).
• Does not yet formally establish "HER2-Low" or "HER2-Ultralow" as official reporting categories but provides best practices for distinguishing subtle IHC differences.
• Clinical Significance: Directly impacts pathology practice worldwide — labs must now more precisely report borderline HER2 results.

🧬 CATEGORY 4 — Comprehensive Review: HER2 Biology & Resistance

10. HER2-Targeted Therapies Beyond Breast Cancer — Nature Reviews Clinical Oncology

Yoon J, Oh DY. HER2-targeted therapies beyond breast cancer – an update. Nat Rev Clin Oncol. 2024 Sep. PMID: 39039196

• Comprehensive review of HER2-targeted therapies in non-breast solid tumors (gastric, colorectal, lung, biliary, endometrial).
• Covers traditional HER2 overexpression/amplification AND emerging ERBB2 mutations as actionable targets.
• Discusses histology-agnostic approval of T-DXd for HER2-overexpressing solid tumors.
• Reviews resistance mechanisms (receptor mutations, bypass signaling via PI3K/AKT, MET amplification) and strategies to overcome them.

Summary Table

Key Themes Across the Evidence

1. T-DXd is displacing T-DM1 across multiple lines of therapy in HER2+ breast cancer, with DESTINY-Breast09 now threatening the THP first-line standard.
2. HER2 thresholds are being redefined — T-DXd active in HER2-low and ultralow disease, requiring pathologists to report IHC 0 vs. 1+ distinctions more carefully.
3. Survival data are maturing — KATHERINE's 8-year follow-up provides the first OS confirmation for T-DM1 in the adjuvant setting.
4. Multi-tumor applicability — T-DXd now has proven OS benefit in gastric cancer (DESTINY-Gastric04) and histology-agnostic approval across HER2+ solid tumors.
5. ILD remains the critical safety signal — occurring in ~12–14% of patients on T-DXd, with rare but fatal events; close monitoring is mandatory.

Bioequivalence Studies on Trastuzumab — Curated Research Report

As of April 28, 2026 | Focused on PK equivalence, clinical equivalence (Phase III), immunogenicity, and regulatory science | Sources: PubMed

Background: Why Bioequivalence Studies Matter for Trastuzumab

1. Analytical/structural similarity (physicochemical and functional characterization)
2. PK bioequivalence — typically demonstrated in healthy volunteers using single-dose parallel-group designs; acceptance criterion: 90% CI for GMR of AUC₀₋∞, AUC₀₋t, and Cmax within 80–125%
3. Clinical equivalence — typically powered for a primary endpoint (e.g., pathological complete response, overall response rate) in Phase III trials
4. Immunogenicity assessment — anti-drug antibody (ADA) incidence and neutralizing antibody testing

SECTION 1 — Phase I PK Bioequivalence Studies (Healthy Volunteers)

1. HLX02 vs. US- and EU-Trastuzumab (Three-Arm Comparison)

Zhou W et al. Comparing the pharmacokinetics, safety, and immunogenicity of HLX02 to US- and EU-approved trastuzumab in healthy Chinese male subjects. Expert Opin Biol Ther. 2023. PMID: 36843059

2. Chia Tai Tianqing Trastuzumab Biosimilar vs. Herceptin® (CTTRZ)

Wang Y et al. A randomized, single-blind, single-dose, parallel-group study in healthy subjects to demonstrate the pharmacokinetic equivalence of trastuzumab and its biosimilar. Expert Opin Drug Metab Toxicol. 2023. PMID: 37526387

3. Recombinant Trastuzumab Biosimilar (Unnamed) vs. Herceptin® — Phase I

Pu H et al. A Randomized, Single-dose, Phase I Clinical Comparison of a Trastuzumab Biosimilar With a Reference Trastuzumab Formulation in Healthy Chinese Male Volunteers. Clin Pharmacol Drug Dev. 2023. PMID: 36317757

4. HL02 vs. US-Trastuzumab — Phase I Dose-Escalation + PK Equivalence

Zhang H et al. Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in healthy Chinese men. Expert Opin Biol Ther. 2022. PMID: 33616478

5. SIBP-01 vs. Herceptin® — Phase I RCT in Chinese Volunteers

Zhou H et al. A randomized Phase I pharmacokinetic trial comparing the potential biosimilar trastuzumab (SIBP-01) with the reference product (Herceptin®) in healthy Chinese male volunteers. Expert Opin Drug Metab Toxicol. 2020. PMID: 32847423

6. DRL_TZ (Dr. Reddy's) vs. EU Herceptin® — Phase I PK Study

Lickliter JD et al. A randomized, double-blind, parallel-group, single-dose comparative pharmacokinetic study of DRL_TZ, a candidate biosimilar of trastuzumab, with Herceptin® (EU) in healthy adult males. Indian J Med Res. 2021. PMID: 35142643

SECTION 2 — Phase I with Immunomodulation Profiling

7. MYL-1401O vs. Herceptin® — Bioequivalence + Immune Phenotyping

Audran R et al. Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study. Sci Rep. 2024. PMID: 38834577

• Trastuzumab infusion induced a transient, weak IL-6 peak at 6 hours and modulated CD16+ cell populations.
• No significant immunomodulatory differences between MYL-1401O and Herceptin® across 60 immune parameters, except for minor CD8+ T cell variation.
• CRA showed identical secretion profiles of IL-6, TNF-α, IL-1β, GM-CSF, IFN-γ, and IL-10.
• Adverse events correlated with IL-2 and IFN-γ responses in the CRA — potentially a predictive safety assay.

SECTION 3 — Phase III Clinical Equivalence Trial

8. HD201 (TROIKA Trial) vs. Reference Trastuzumab — Phase III Neoadjuvant Equivalence

Pivot X et al. Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting. JAMA Oncol. 2022. PMID: 35238873

• Safety and immunogenicity comparable between arms; 86% of patients had trastuzumab-specific AEs of special interest.
• PK and ADA profiles were similar.
• Significance: One of the most rigorous clinical equivalence datasets for a trastuzumab biosimilar; supports biosimilar approval across neoadjuvant, adjuvant, and metastatic indications via extrapolation.

SECTION 4 — Regulatory Science Review

9. Optimizing Biosimilar PK Similarity: FDA vs. EMA Regulatory Comparison

Kiely P, Murray D. Optimizing biosimilar development: current approaches to demonstrating pharmacokinetic and analytical similarity and a proposal for a single reference approach. Expert Opin Biol Ther. 2025. PMID: 40035204

• Reviews biosimilar approvals by FDA and EMA; identifies divergent requirements for non-local reference medicinal products (e.g., US vs. EU Herceptin® as reference).
• Argues that replicated PK bioequivalence studies using different regional reference products are often redundant when critical quality attributes are analytically similar.
• Proposes a "single reference approach" — if biosimilarity is established against one regional reference, a bridging PK study against the other reference should suffice.
• Directly impacts trastuzumab biosimilar development pathways globally.

Summary Table

Key Patterns Across the Evidence

Humira (Adalimumab) and Relapsed Non-Hodgkin Lymphoma

⚠️ Critical Finding Upfront

What is Adalimumab?

• Rheumatoid arthritis (RA)
• Ankylosing spondylitis
• Psoriatic arthritis
• Juvenile idiopathic arthritis
• Plaque psoriasis
• Crohn's disease and ulcerative colitis
• Hidradenitis suppurativa
• Uveitis

The Real Relationship: Adalimumab as a Lymphoma Risk Factor

Mechanism of Concern

• Impair immune surveillance and tumour cell elimination
• Reduce NK cell and cytotoxic T-cell activity against lymphoma cells
• Promote an immunosuppressed environment permissive to lymphomagenesis
• Reactivate latent Epstein-Barr virus (EBV), a known driver of lymphomagenesis

Evidence from Clinical Studies

Song J et al. Risk of hematologic malignancies in psoriasis and RA patients using long-term TNF-α inhibitors. Sci Rep. 2025. PMID: 40055388

• Nationwide cohort (N=7,645 TNFi users vs. non-users) in RA and psoriasis patients
• Adalimumab was associated with a significantly increased risk of leukemia (aHR 3.36; 95% CI 1.65–6.84; p<0.001)
• Infliximab was associated with increased lymphoma risk (aHR 2.49; p<0.01)
• Accumulated TNFi prescription over 2 years increased haematological malignancy risk
• Conclusion: TNFi prescriptions, including adalimumab, should be made with careful haematological risk assessment

Muller M et al. TNF Inhibitors and Risk of Malignancy in Patients with IBD. J Crohns Colitis. 2021. PMID: 32915970

• Systematic review of 28 studies, 298,717 IBD patients
• 692 malignancies in TNFi-treated patients; 15.3% were haematological malignancies
• One study found increased lymphoma risk with TNFi exposure; 10 studies found no significant overall malignancy association
• Conclusion: No consistent increased malignancy risk in IBD populations, but haematological malignancies remain a class concern

"A meta-analysis of data from 9 randomized controlled trials of 3,493 rheumatoid arthritis patients treated with adalimumab or infliximab demonstrated an increased risk of solid-organ malignancies. This increased risk proved to be dose-dependent." — Fitzpatrick's Dermatology, Vol. 1–2

"The largest observational study as of this writing suggests a slightly higher risk of lymphoma associated with adalimumab." — Fitzpatrick's Dermatology

Contraindication: Adalimumab in Patients WITH Lymphoma

• Active malignancy, including NHL
• History of lymphoma — due to risk of reactivation or promotion of residual/relapsed disease
• Patients on concurrent thiopurines (azathioprine/6-mercaptopurine) have an especially elevated hepatosplenic T-cell lymphoma risk with TNFi combination therapy

What Are the Actual Treatments for Relapsed NHL?

Summary